MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated

mbs303MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. TheMBS303 Track lurus idaman pembalap drag, mengadu peruntungan kemenangan dengan MBS 303 nominal hadiah hingga 69juta rupiah!